Drug chiefs ponder how to improve industry's reputation
BMJ 2005; 330 doi: https://doi.org/10.1136/bmj.330.7502.1229-a (Published 26 May 2005) Cite this as: BMJ 2005;330:1229- Bob Burton
- Canberra
Drug industry executives and advisers told a conference in Sydney last week that the poor public standing of the industry was hindering its ability to sell its products at higher prices to government agencies as well as its attempts to address public criticism.
Introducing a panel discussion on reputation management, Kristin Austin, director of the public relations company Ruder Finn, said that a review of coverage of the industry in the Sydney print media showed 30 positive stories in the preceding year but 40 critical stories.
“Each negative story requires six …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.